The WACC of Protalix Biotherapeutics Inc (PLX) is 6.4%.
| Range | Selected | |
| Cost of equity | 5.60% - 7.60% | 6.60% |
| Tax rate | 1.80% - 3.30% | 2.55% |
| Cost of debt | 4.90% - 7.70% | 6.30% |
| WACC | 5.2% - 7.5% | 6.4% |
| Category | Low | High |
| Long-term bond rate | 3.9% | 4.4% |
| Equity market risk premium | 4.6% | 5.6% |
| Adjusted beta | 0.38 | 0.49 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 5.60% | 7.60% |
| Tax rate | 1.80% | 3.30% |
| Debt/Equity ratio | 1 | 1 |
| Cost of debt | 4.90% | 7.70% |
| After-tax WACC | 5.2% | 7.5% |
| Selected WACC | 6.4% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for PLX:
cost_of_equity (6.60%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.38) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.